EFSA Limits Curcumin to 120mg Daily and Mandates Liver Warning for High Bioavailability Blends

The European Food Safety Authority has released a definitive scientific opinion regarding the safety of curcuminoids in food supplements. If you are currently formulating turmeric products with piperine or micellar delivery systems, your current dosages likely exceed the new safety threshold.

New ADI and Bioavailability Constraints

The panel established an Acceptable Daily Intake of 1.2mg per kg of body weight, which translates to roughly 84mg for a 70kg adult. However, for food supplements, the maximum permitted level is now capped at 120mg of curcuminoids per day. This ruling specifically targets the increased systemic exposure caused by bioavailability enhancers.

• Maximum daily dose capped at 120mg curcuminoids.
• Mandatory label warning: Not to be consumed by individuals with hepatobiliary diseases.
• Verification of piperine content required to ensure it does not exceed 5mg per dose.
• Exclusion of curcumin-cyclodextrin complexes from standard safety categories.

Procurement and Formulation Impact

High-load 95 percent curcumin extracts priced at 85 EUR per kg will see a demand shift. Formulators should pivot to whole-root powders or lower concentration extracts to meet the 120mg ceiling while maintaining pill mass. If you have Q4 production runs scheduled for 500mg curcuminoid profiles, cancel them now to avoid unsellable inventory.

The transition period for existing stock is expected to be six months. Brands using patented delivery systems like phytosomes or liquid micelles must provide specific pharmacokinetic data to prove their 120mg equivalent does not lead to hepatotoxicity. Expect increased scrutiny from national authorities in France and Germany starting September.